Subtype
Male Reproductive System Carcinoma
CI-CAN-00003134Explore in graph →
451 active trials16 approved drugs20 evidence items
- NCIt
- C181196
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003134Explore in graph →
Clinical trials
1,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (190)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 211 | National Cancer Institute (NCI)NIH | 2 | Feb 26, 2018 | clinicaltrials |
| NCT02025361 | Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy | completed | Phase 4 | 422 | Bagcilar Training and Research HospitalOTHER_GOV | 1 | Jan 18, 2018 |
| clinicaltrials |
| NCT03196388 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer(ENZART) | unknown | Phase 2 | 70 | Fundación Canaria Instituto de Investigación Sanitaria de CanariasOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01949519 | Docetaxel and Lycopene in Metastatic Prostate Cancer | completed | Phase 1 | 24 | Medical University of South CarolinaOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01433913 | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02342626 | Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer | completed | N/A | 140 | University of RochesterOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT03356912 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | unknown | Phase 2 | 220 | Consorzio OncotechOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT01200810 | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2017 | clinicaltrials |
| NCT03356444 | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 140 | West China HospitalOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00466752 | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | completed | Phase 2 | 5 | University of WashingtonOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02705469 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 44 | Zenith EpigeneticsINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02564549 | MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca | terminated | N/A | 28 | Virginia Commonwealth UniversityOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02869412 | Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy | completed | N/A | 56 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00589472 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer(TARGET) | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT01145508 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT03285815 | Prostate Cancer - Localized Adenocarcinoma Proton Therapy | unknown | N/A | 156 | National Cancer Center, KoreaOTHER_GOV | 1 | Sep 18, 2017 | clinicaltrials |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 4 | University of Southern CaliforniaOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT01594918 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 25 | Rahul AggarwalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00243321 | High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer | completed | N/A | 27 | Virginia Commonwealth UniversityOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT03074032 | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 17 | Avionco LLCINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01023061 | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer(RAD1) | completed | Phase 2 | 24 | University of WashingtonOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT02429804 | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00486642 | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 24, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | terminated | Phase 2 | 34 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02370355 | Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer | terminated | — | 24 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01450683 | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | terminated | Phase 2 | 4 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02440308 | 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01050842 | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01606982 | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Feb 17, 2017 | clinicaltrials |
| NCT02421575 | Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance | terminated | Early Phase 1 | 4 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 2, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT01347788 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT02964351 | microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer | unknown | — | 120 | Assuta Medical CenterOTHER | 0 | Nov 16, 2016 | clinicaltrials |
| NCT02002455 | Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI(Flucipro) | completed | Phase 2 | 26 | Turku University HospitalOTHER_GOV | 1 | Oct 21, 2016 | clinicaltrials |
| NCT02935023 | Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 47 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT02279576 | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)(PAZOPEN-SOGUG) | terminated | Phase 2 | 4 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 26, 2018source: clinicaltrials